Travere Therapeutics, Inc. (TVTX)

NGM – Real vaqt narxi. Valyuta: USD

58.85

-0.18 (-0.30%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

60.19

+1.34 (2.28%)

Bozordan keyin: Jun 26, 2026, 6:33 PM EDT

16.06.2026

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research and development and CMO.

11.06.2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as i.

08.06.2026

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

04.06.2026

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerulosclerosis (FSGS). Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Pati.

02.06.2026

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

02.06.2026

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to develop and ‌commercialize an experimental kidney disease drug in a deal worth up to $1.14 billion.

02.06.2026

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia. “Civorebrutinib represents a strategic and complementary.

Videolar

No Data

There is no data to display

Press-relizlar

16.06.2026

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

11.06.2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04.06.2026

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

02.06.2026

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Travere Therapeutics, Inc. (TVTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Videolar

No Data

Press-relizlar

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Videolar

No Data

Press-relizlar

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Search stocks

Travere Therapeutics, Inc. (TVTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Videolar

No Data

Press-relizlar

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Videolar

No Data

Press-relizlar

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases